Lulivas 1% Cream contains luliconazole 1% w/w, a topical antifungal agent belonging to the imidazole class, indicated for the treatment of superficial fungal infections of the skin. Luliconazole exhibits broad-spectrum antifungal activity against dermatophytes, yeasts, and molds by inhibiting the biosynthesis of ergosterol, an essential component of fungal cell membranes, thereby disrupting membrane integrity and leading to fungal cell death. This cream is primarily prescribed for conditions such as tinea corporis, tinea cruris, and tinea pedis. The formulation allows for effective penetration into the stratum corneum, ensuring targeted action at the site of infection with minimal systemic absorption. Lulivas 1% Cream is applied topically once daily, typically for a duration ranging from one to two weeks depending on the severity and location of the infection. It is generally well-tolerated; however, mild adverse reactions such as local irritation, burning sensation, or erythema may occur. Use should be avoided in patients with known hypersensitivity to luliconazole or any cream components. As with all antifungal treatments, adherence to the full prescribed course is essential to prevent recurrence and resistance. Consultation with a healthcare professional is recommended prior to use, especially in pregnant or lactating women.